miRNA作为卵巢癌早期诊断标志物的研究进展  

Research progress of miRNAs as early diagnostic biomarkers for ovarian cancer

作　　者：周鸣卓 曲红梅[1] ZHOU Mingzhuo;QU Hongmei(School of Medicine,Northwest Minzu University,Gansu,Lanzhou 730030,China)

机构地区：[1]西北民族大学医学部,兰州市730030

出　　处：《河北医药》2025年第2期313-317,共5页Hebei Medical Journal

基　　金：国家级科研项目培育项目(编号:31920210003)。

摘　　要：卵巢癌是常见的妇科恶性肿瘤之一,绝大多数患者确诊已是晚期,早期诊断卵巢癌至关重要。微小核糖核酸(miRNA)是新兴的检测卵巢癌的生物标志物,相对于血清标志物早期检测卵巢癌的低特异性、高假阳性率,其显示出了巨大潜力,随着研究的深入,一些检测方法也更加成熟和新颖,这对卵巢癌的早期诊断提供了更高的可能性。本文结合国内外研究进展,总结miRNA在组织、血液、尿液中早期检测卵巢癌的潜在作用,以期提供有力的科学依据。Ovarian cancer is one of the common gynecological malignancies.However,the vast majority of patients have been initially diagnosed as advanced ovarian cancer.An early detection of ovarian cancer is crucial.MicroRNAs(miRNAs)are emerging biomarkers for diagnosing ovarian cancer,showing a great potential with the low specificity and high false-positive rate compared with serum markers.With the deepening of research,some detection methods are more mature and novel to provide higher possibilities for an early diagnosis of ovarian cancer.Combined with the research progress at home and abroad,this article summarized the potential role of miRNAs in tissue,blood and urine in the early detection of ovarian cancer,thus providing a strong scientific basis.

关 键 词：卵巢癌 MIRNA 肿瘤标记物 

分 类 号：R737.31[医药卫生—肿瘤]